Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 75 (3), 690-696

Tolerance to Nifurtimox and Benznidazole in Adult Patients With Chronic Chagas' Disease

Affiliations

Tolerance to Nifurtimox and Benznidazole in Adult Patients With Chronic Chagas' Disease

Yves Jackson et al. J Antimicrob Chemother.

Abstract

Background: Current options for Chagas' disease treatment are restricted to benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared their tolerance in adults in a non-endemic country.

Objectives: To compare the completion rates and drug tolerance in a cohort of patients treated according to current guidelines.

Patients and methods: We analysed the medical records of all Chagas' disease patients aged 18 years or over who started antiparasitic treatment at the Geneva University Hospitals, Switzerland, from 2008 to 2016. We recorded treatment duration and all adverse events.

Results: We included 176 patients, 92 and 84 of whom received benznidazole or nifurtimox, respectively. The overall treatment completion rate was 62.5%, without a significant difference between the groups (P=0.436). Most patients (89.8%) suffered at least one adverse event. Those receiving nifurtimox had more events (6.2 versus 3.5, P<0.001). Mucocutaneous symptoms predominated in the benznidazole group, whereas digestive symptoms were most frequent with nifurtimox. Neuropsychiatric events frequently occurred in both groups, most notably in patients receiving nifurtimox. Arthralgia, dyspnoea, sensitive neuropathy and pruritus were independent predictors of treatment interruption.

Conclusions: Currently recommended drug regimens for Chagas' disease are not well tolerated and entail frequent treatment discontinuation irrespective of the drug used. This highlights the need to improve treatment tolerance in adults with Chagas' disease with new therapeutic options.

Figures

Figure 1.
Figure 1.
Kaplan–Meier estimates of time to treatment interruption in adult patients treated for Chagas’ disease with benznidazole (n=92, continuous line) or nifurtimox (n=84, broken line) (log-rank test, P=0.436).

Similar articles

See all similar articles

References

    1. WHO. Chagas Disease (American Trypanosomiasis). 2019. https://www.who.int/en/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis).
    1. Requena-Mendez A, Aldasoro E, de Lazzari E. et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 2015; 9: e0003540.. - PMC - PubMed
    1. Manne-Goehler J, Umeh CA, Montgomery SP. et al. Estimating the burden of Chagas Disease in the United States. PLoS Negl Trop Dis 2016; 10: e0005033.. - PMC - PubMed
    1. Kratz JM, Garcia Bournissen F, Forsyth CJ. et al. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev Clin Pharmacol 2018; 11: 943–57. - PubMed
    1. Pinheiro E, Brum-Soares L, Reis R. et al. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America. Rev Soc Bras Med Trop 2017; 50: 296–300. - PubMed
Feedback